JP2005534615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534615A5 JP2005534615A5 JP2003571313A JP2003571313A JP2005534615A5 JP 2005534615 A5 JP2005534615 A5 JP 2005534615A5 JP 2003571313 A JP2003571313 A JP 2003571313A JP 2003571313 A JP2003571313 A JP 2003571313A JP 2005534615 A5 JP2005534615 A5 JP 2005534615A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- derivative
- tenascin
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims 15
- 102000007000 Tenascin Human genes 0.000 claims 10
- 108010008125 Tenascin Proteins 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 231100000617 superantigen Toxicity 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims 1
- 101000666340 Homo sapiens Tenascin Proteins 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 150000001615 biotins Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 102000057345 human TNC Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 238000003118 sandwich ELISA Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- -1 superantigens Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35929902P | 2002-02-26 | 2002-02-26 | |
| PCT/IT2003/000098 WO2003072608A1 (en) | 2002-02-26 | 2003-02-20 | Anti-human tenascin monoclonal antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005534615A JP2005534615A (ja) | 2005-11-17 |
| JP2005534615A5 true JP2005534615A5 (https=) | 2006-04-06 |
| JP4488746B2 JP4488746B2 (ja) | 2010-06-23 |
Family
ID=27766061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571313A Expired - Lifetime JP4488746B2 (ja) | 2002-02-26 | 2003-02-20 | 抗−ヒトテネイシンモノクローナル抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7438908B2 (https=) |
| EP (1) | EP1478667B1 (https=) |
| JP (1) | JP4488746B2 (https=) |
| KR (1) | KR101048894B1 (https=) |
| CN (1) | CN1317303C (https=) |
| AR (1) | AR038700A1 (https=) |
| AT (1) | ATE480564T1 (https=) |
| AU (1) | AU2003215900B2 (https=) |
| BR (1) | BR0307994A (https=) |
| CA (1) | CA2475395C (https=) |
| CY (1) | CY1111108T1 (https=) |
| DE (1) | DE60334076D1 (https=) |
| DK (1) | DK1478667T3 (https=) |
| ES (1) | ES2352180T3 (https=) |
| MX (1) | MXPA04008216A (https=) |
| PL (1) | PL213216B1 (https=) |
| PT (1) | PT1478667E (https=) |
| SI (1) | SI1478667T1 (https=) |
| WO (1) | WO2003072608A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040105A1 (it) * | 2004-02-27 | 2004-05-27 | Tecnogen Scpa | Anticorpo monoclonale antitenascina umana. |
| EP2057193B1 (en) | 2006-08-04 | 2013-12-18 | Novartis AG | Ephb3-specific antibody and uses thereof |
| CA2711843C (en) | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
| FR2930036B1 (fr) * | 2008-04-11 | 2010-05-07 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une hypertension arterielle pulmonaire. |
| US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| US8470542B2 (en) | 2008-12-01 | 2013-06-25 | Laboratory Corporation Of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| SG172984A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-2 expression |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| WO2011060076A1 (en) * | 2009-11-10 | 2011-05-19 | Amgen Inc. | Anti-c-mpl antibodies |
| WO2012051498A2 (en) | 2010-10-15 | 2012-04-19 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| US8959638B2 (en) | 2011-03-29 | 2015-02-17 | Mcafee, Inc. | System and method for below-operating system trapping and securing of interdriver communication |
| US8966624B2 (en) | 2011-03-31 | 2015-02-24 | Mcafee, Inc. | System and method for securing an input/output path of an application against malware with a below-operating system security agent |
| US9032525B2 (en) | 2011-03-29 | 2015-05-12 | Mcafee, Inc. | System and method for below-operating system trapping of driver filter attachment |
| US9262246B2 (en) | 2011-03-31 | 2016-02-16 | Mcafee, Inc. | System and method for securing memory and storage of an electronic device with a below-operating system security agent |
| US8863283B2 (en) | 2011-03-31 | 2014-10-14 | Mcafee, Inc. | System and method for securing access to system calls |
| US9087199B2 (en) | 2011-03-31 | 2015-07-21 | Mcafee, Inc. | System and method for providing a secured operating system execution environment |
| US9038176B2 (en) | 2011-03-31 | 2015-05-19 | Mcafee, Inc. | System and method for below-operating system trapping and securing loading of code into memory |
| US9317690B2 (en) | 2011-03-28 | 2016-04-19 | Mcafee, Inc. | System and method for firmware based anti-malware security |
| US8966629B2 (en) | 2011-03-31 | 2015-02-24 | Mcafee, Inc. | System and method for below-operating system trapping of driver loading and unloading |
| US8813227B2 (en) | 2011-03-29 | 2014-08-19 | Mcafee, Inc. | System and method for below-operating system regulation and control of self-modifying code |
| US8925089B2 (en) | 2011-03-29 | 2014-12-30 | Mcafee, Inc. | System and method for below-operating system modification of malicious code on an electronic device |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| WO2013088140A2 (en) * | 2011-12-12 | 2013-06-20 | Isis Innovation Limited | Biomarker and use thereof |
| US9657098B2 (en) | 2013-03-15 | 2017-05-23 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| AU2015321462B2 (en) | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| GB201602413D0 (en) * | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687732A (en) * | 1983-06-10 | 1987-08-18 | Yale University | Visualization polymers and their application to diagnostic medicine |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994021293A1 (en) * | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US5482698A (en) * | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
| ATE335072T1 (de) * | 1993-05-28 | 2006-08-15 | Scripps Research Inst | Methoden für inhibition der cd14-abhängigen zellaktivierung |
| US6335014B1 (en) * | 1998-06-17 | 2002-01-01 | The Institute Of Physical And Chemical Research | Medicament for suppressing cancer metastasis |
| ITRM20020128A1 (it) | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2003
- 2003-02-20 ES ES03743010T patent/ES2352180T3/es not_active Expired - Lifetime
- 2003-02-20 US US10/505,747 patent/US7438908B2/en not_active Expired - Lifetime
- 2003-02-20 DK DK03743010.5T patent/DK1478667T3/da active
- 2003-02-20 BR BR0307994-5A patent/BR0307994A/pt not_active IP Right Cessation
- 2003-02-20 DE DE60334076T patent/DE60334076D1/de not_active Expired - Lifetime
- 2003-02-20 JP JP2003571313A patent/JP4488746B2/ja not_active Expired - Lifetime
- 2003-02-20 AU AU2003215900A patent/AU2003215900B2/en not_active Ceased
- 2003-02-20 CN CNB038046342A patent/CN1317303C/zh not_active Expired - Fee Related
- 2003-02-20 WO PCT/IT2003/000098 patent/WO2003072608A1/en not_active Ceased
- 2003-02-20 PL PL372803A patent/PL213216B1/pl unknown
- 2003-02-20 CA CA2475395A patent/CA2475395C/en not_active Expired - Fee Related
- 2003-02-20 SI SI200331899T patent/SI1478667T1/sl unknown
- 2003-02-20 EP EP03743010A patent/EP1478667B1/en not_active Expired - Lifetime
- 2003-02-20 PT PT03743010T patent/PT1478667E/pt unknown
- 2003-02-20 KR KR1020047013068A patent/KR101048894B1/ko not_active Expired - Fee Related
- 2003-02-20 AT AT03743010T patent/ATE480564T1/de active
- 2003-02-20 MX MXPA04008216A patent/MXPA04008216A/es active IP Right Grant
- 2003-02-25 US US10/372,719 patent/US20040005643A1/en not_active Abandoned
- 2003-02-26 AR ARP030100622A patent/AR038700A1/es not_active Application Discontinuation
-
2008
- 2008-09-17 US US12/232,431 patent/US8048417B2/en not_active Expired - Fee Related
-
2010
- 2010-12-01 CY CY20101101107T patent/CY1111108T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005534615A5 (https=) | ||
| CA2475395A1 (en) | Anti-human tenascin monoclonal antibody | |
| ES2305879T3 (es) | Metodo para el tratamiento de la esclerosis multiple mediante inhibicion de la actividad il-17. | |
| ES2341625T3 (es) | Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. | |
| RU2236251C2 (ru) | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии | |
| CN107029244B (zh) | 抗her2抗体-药物偶联物及其应用 | |
| EP1446418B1 (en) | Integrin targeting compounds | |
| CN110545846A (zh) | 用于光免疫疗法的治疗组合物和相关方法 | |
| JP6577016B2 (ja) | 治療及び診断のための抗コラーゲン抗体 | |
| JP2021502810A5 (https=) | ||
| JPH0596A (ja) | ヒト腫瘍致死因子αに対するモノクローナル抗体 | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| KR20020000223A (ko) | 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법 | |
| US9701754B1 (en) | Covalent disulfide-linked diabodies and uses thereof | |
| KR20000015893A (ko) | 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도 | |
| JP2003096096A (ja) | 腫瘍壊死因子結合リガンド | |
| JP2005514409A (ja) | Ｍｕｃ１８抗原に対する抗体の使用 | |
| CA2451680A1 (en) | Human dr4 antibodies and uses thereof | |
| JP2007504280A5 (https=) | ||
| JP2006514627A5 (https=) | ||
| JP2014515600A5 (https=) | ||
| Schliemann et al. | Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| CN115558029B (zh) | 靶向pd-1的双特异性抗体、及其制备和应用 | |
| CN118852442A (zh) | 抗ptk7抗体及其用途 |